Last reviewed · How we verify
NCT05868629
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
trial testing Non-investigational in Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors in 40 participants. Currently enrolling.
3 March 2028
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 6 February 2024 |
| Primary completion | 3 March 2028 |
| Estimated completion | 3 March 2028 |
| Sites | 8 locations across United States |
Drugs / interventions tested
- Non-investigational
Conditions studied
- Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors — all drugs for Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
Adults 1 to 100, any sex, with Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (1 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metastatic solid tumors for whom a decision has already been made to be treated with dabrafenib and trametinib, irrespective of the trial participation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeted therapies in pediatric oncology: A start.
Shah N. · · 2026 · PMID 41994561 · DOI 10.1016/j.omton.2026.201146
Verify or expand the search:
- PubMed search for NCT05868629
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05868629 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 1 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05868629.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing